包括自体福尔马林固定肿瘤疫苗在内的综合治疗后骨转移性乳腺癌1年及以上的临床完全缓解率

Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine.

作者信息

Kuranishi Fumito, Imaoka Yuki, Sumi Yuusuke, Uemae Yoji, Yasuda-Kurihara Hiroko, Ishihara Takeshi, Miyazaki Tsubasa, Ohno Tadao

机构信息

Department of Surgery, Innoshima-Ishikai Hospital, Innoshima, Onomichi, Hiroshima 722-2211, Japan.

Cell-Medicine, Inc., 2-1-6 Sengen, Tsukuba, Ibaraki 305-0074, Japan.

出版信息

Int J Breast Cancer. 2018 Jan 22;2018:4879406. doi: 10.1155/2018/4879406. eCollection 2018.

DOI:10.1155/2018/4879406

PMID:29576883

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5822812/

Abstract

INTRODUCTION

No effective treatment has been developed for bone-metastatic breast cancer. We found 3 cases with clinical complete response (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively including autologous formalin-fixed tumor vaccine (AFTV).

PATIENTS AND METHODS

AFTV was prepared individually for each patient from their own formalin-fixed and paraffin-embedded breast cancer tissues.

RESULTS

Three patients maintained cCR status of the bone metastasis for 17 months or more. Rate of cCR for 1 year or more appeared to be 15% (3/20) after comprehensive treatments including AFTV. The median overall survival time (60.0 months) and the 3- to 8-year survival rates after diagnosis of bone metastasis were greater than those of historical control cohorts in Japan (1988-2002) and in the nationwide population-based cohort study of Denmark (1999-2007).

CONCLUSION

Bone-metastatic breast cancer may be curable after comprehensive treatments including AFTV, although larger scale clinical trial is required.

摘要

引言

目前尚未开发出针对骨转移性乳腺癌的有效治疗方法。我们发现3例骨转移临床完全缓解（cCR）的病例，且回顾性研究队列中接受包括自体福尔马林固定肿瘤疫苗（AFTV）在内的综合治疗的患者总生存期更长。

患者与方法

从每位患者自身福尔马林固定、石蜡包埋的乳腺癌组织中单独制备AFTV。

结果

3例患者骨转移的cCR状态维持了17个月或更长时间。在包括AFTV在内的综合治疗后，1年或更长时间的cCR率似乎为15%（3/20）。骨转移诊断后的中位总生存时间（60.0个月）以及3至8年生存率高于日本历史对照队列（1988 - 2002年）和丹麦全国基于人群的队列研究（1999 - 2007年）。